[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcdstvyxs9y3UUdMNxVzfhvPPCPk9m20OZxNFR4skSh8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":49,"rows":56},"Singapore National Eye Centre",[4],82,false,11,7,7201,4,65,[14,17,19,21,23,25,28,30],{"name":15,"count":16},"Myopia",14,{"name":18,"count":16},"Dry Eye",{"name":20,"count":9},"Glaucoma",{"name":22,"count":11},"Dry Eyes",{"name":24,"count":11},"Polypoidal Choroidal Vasculopathy",{"name":26,"count":27},"Pachychoroid Disease",3,{"name":29,"count":27},"Pterygium",{"name":31,"count":32},"Keratoconus",2,[34,39,44],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03140358","The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)","2024-12-31","Atropine sulfate 0.01%",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06765603","Evaluating the Efficacy of the Combination of Multi-zonal Contact Lens and Atropine for Controlling Myopia Progression","2028-12-31","Atropine 0.025%",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT07249216","Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting","2029-06","Faricimab",[50,51,52,53,54,55],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[57,81,103,127,145,173,191,217,244,270,288,311,335,359,384,408,432,458,476,500,518,541],{"intervention":38,"totalTrials":58,"cells":59},1,{"EARLY_PHASE1":60,"PHASE1":63,"PHASE2":65,"PHASE3":67,"PHASE4":77,"NA":79},{"trials":61,"activeCount":62},[],0,{"trials":64,"activeCount":62},[],{"trials":66,"activeCount":62},[],{"trials":68,"activeCount":58,"soonestReadout":37},[69],{"nctId":35,"briefTitle":36,"status":70,"phases":71,"primaryCompletion":37,"completion":72,"start":73,"enrollment":74,"conditions":75,"interventions":76},"ACTIVE_NOT_RECRUITING",[53],"2025-12-31","2017-04-21",300,[15],[38],{"trials":78,"activeCount":62},[],{"trials":80,"activeCount":62},[],{"intervention":43,"totalTrials":58,"cells":82},{"EARLY_PHASE1":83,"PHASE1":85,"PHASE2":87,"PHASE3":97,"PHASE4":99,"NA":101},{"trials":84,"activeCount":62},[],{"trials":86,"activeCount":62},[],{"trials":88,"activeCount":58,"soonestReadout":42},[89],{"nctId":40,"briefTitle":41,"status":90,"phases":91,"primaryCompletion":42,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":96},"NOT_YET_RECRUITING",[52],"2029-12-31","2025-02-01",180,[15],[43],{"trials":98,"activeCount":62},[],{"trials":100,"activeCount":62},[],{"trials":102,"activeCount":62},[],{"intervention":48,"totalTrials":58,"cells":104},{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":113,"NA":115},{"trials":106,"activeCount":62},[],{"trials":108,"activeCount":62},[],{"trials":110,"activeCount":62},[],{"trials":112,"activeCount":62},[],{"trials":114,"activeCount":62},[],{"trials":116,"activeCount":58,"soonestReadout":47},[117],{"nctId":45,"briefTitle":46,"status":118,"phases":119,"primaryCompletion":47,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},"RECRUITING",[55],"2029-07","2025-07-18",117,[124],"Age Related Macular Degeneration",[48,126],"Ranibizumab",{"intervention":126,"totalTrials":58,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":139},{"trials":130,"activeCount":62},[],{"trials":132,"activeCount":62},[],{"trials":134,"activeCount":62},[],{"trials":136,"activeCount":62},[],{"trials":138,"activeCount":62},[],{"trials":140,"activeCount":58,"soonestReadout":47},[141],{"nctId":45,"briefTitle":46,"status":118,"phases":142,"primaryCompletion":47,"completion":120,"start":121,"enrollment":122,"conditions":143,"interventions":144},[55],[124],[48,126],{"intervention":146,"totalTrials":58,"cells":147},"5 Fluorouracil with hyaluronic acid",{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":171},{"trials":149,"activeCount":62},[],{"trials":151,"activeCount":62},[],{"trials":153,"activeCount":62},[],{"trials":155,"activeCount":62},[],{"trials":157,"activeCount":62},[158],{"nctId":159,"briefTitle":160,"status":161,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":169},"NCT00607685","5FU vs 5FU With Viscoelastic Formulation for the Prevention of Scarring Post-trabeculectomy","COMPLETED",[54],"2010-01","2008-02",50,[20,167,168],"Trabeculectomy","Wound Healing",[146,170],"5 Fluorouracil",{"trials":172,"activeCount":62},[],{"intervention":170,"totalTrials":58,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":189},{"trials":176,"activeCount":62},[],{"trials":178,"activeCount":62},[],{"trials":180,"activeCount":62},[],{"trials":182,"activeCount":62},[],{"trials":184,"activeCount":62},[185],{"nctId":159,"briefTitle":160,"status":161,"phases":186,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":187,"interventions":188},[54],[20,167,168],[146,170],{"trials":190,"activeCount":62},[],{"intervention":192,"totalTrials":58,"cells":193},"2% guttae ganciclovir",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":202,"NA":215},{"trials":195,"activeCount":62},[],{"trials":197,"activeCount":62},[],{"trials":199,"activeCount":62},[],{"trials":201,"activeCount":62},[],{"trials":203,"activeCount":62},[204],{"nctId":205,"briefTitle":206,"status":161,"phases":207,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT02943057","Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis \u002F Endotheliitis",[54],"2024-01","2024-11-30","2016-10",25,[213],"Cytomegalovirus Infections",[192],{"trials":216,"activeCount":62},[],{"intervention":218,"totalTrials":58,"cells":219},"Aflibercept Injection [Eylea]",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":242},{"trials":221,"activeCount":62},[],{"trials":223,"activeCount":62},[],{"trials":225,"activeCount":62},[],{"trials":227,"activeCount":62},[],{"trials":229,"activeCount":62},[230],{"nctId":231,"briefTitle":232,"status":233,"phases":234,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":241},"NCT03197480","Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME","UNKNOWN",[54],"2020-12-31","2021-03-01","2019-04-17",36,[240],"Diabetic Macular Edema",[218],{"trials":243,"activeCount":62},[],{"intervention":245,"totalTrials":58,"cells":246},"Treat and Extend with Aflibercept 2mg",{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":268},{"trials":248,"activeCount":62},[],{"trials":250,"activeCount":62},[],{"trials":252,"activeCount":62},[],{"trials":254,"activeCount":62},[],{"trials":256,"activeCount":62},[257],{"nctId":258,"briefTitle":259,"status":161,"phases":260,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":266},"NCT03117634","An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy",[54],"2020-06-30","2021-01-31","2017-12-01",54,[124,24],[245,267],"Fixed Dosing with Aflibercept 2mg",{"trials":269,"activeCount":62},[],{"intervention":267,"totalTrials":58,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":286},{"trials":273,"activeCount":62},[],{"trials":275,"activeCount":62},[],{"trials":277,"activeCount":62},[],{"trials":279,"activeCount":62},[],{"trials":281,"activeCount":62},[282],{"nctId":258,"briefTitle":259,"status":161,"phases":283,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":284,"interventions":285},[54],[124,24],[245,267],{"trials":287,"activeCount":62},[],{"intervention":289,"totalTrials":58,"cells":290},"Atropine Eye drops",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":307,"NA":309},{"trials":292,"activeCount":62},[],{"trials":294,"activeCount":62},[],{"trials":296,"activeCount":62},[],{"trials":298,"activeCount":62},[299],{"nctId":300,"briefTitle":301,"status":233,"phases":302,"start":303,"enrollment":304,"conditions":305,"interventions":306},"NCT00371124","Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children",[52,53],"2006-03",400,[15],[289],{"trials":308,"activeCount":62},[],{"trials":310,"activeCount":62},[],{"intervention":312,"totalTrials":58,"cells":313},"Bevacizumab",{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":331,"NA":333},{"trials":315,"activeCount":62},[],{"trials":317,"activeCount":62},[],{"trials":319,"activeCount":62},[],{"trials":321,"activeCount":62},[322],{"nctId":323,"briefTitle":324,"status":233,"phases":325,"completion":326,"start":327,"enrollment":165,"conditions":328,"interventions":330},"NCT00344617","Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy",[53],"2008-05","2006-06",[329,24],"Choroidal Neovascularisation",[312],{"trials":332,"activeCount":62},[],{"trials":334,"activeCount":62},[],{"intervention":336,"totalTrials":58,"cells":337},"Travatan\u002F Timolol\u002FAzopt",{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":344,"PHASE4":355,"NA":357},{"trials":339,"activeCount":62},[],{"trials":341,"activeCount":62},[],{"trials":343,"activeCount":62},[],{"trials":345,"activeCount":62},[346],{"nctId":347,"briefTitle":348,"status":233,"phases":349,"primaryCompletion":350,"start":351,"enrollment":352,"conditions":353,"interventions":354},"NCT00980473","Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma",[53],"2011-09","2007-09",80,[20],[336],{"trials":356,"activeCount":62},[],{"trials":358,"activeCount":62},[],{"intervention":360,"totalTrials":58,"cells":361},"Autologous serum eyedrops",{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":376,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":363,"activeCount":62},[],{"trials":365,"activeCount":62},[366],{"nctId":367,"briefTitle":368,"status":161,"phases":369,"primaryCompletion":370,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":375},"NCT01089985","Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye",[51],"2011-12","2010-07",10,[374],"Xerophthalmia",[360],{"trials":377,"activeCount":62},[],{"trials":379,"activeCount":62},[],{"trials":381,"activeCount":62},[],{"trials":383,"activeCount":62},[],{"intervention":385,"totalTrials":58,"cells":386},"Autologous Plasma Eye Drop",{"EARLY_PHASE1":387,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":388,"activeCount":62},[389],{"nctId":390,"briefTitle":391,"status":392,"phases":393,"primaryCompletion":394,"completion":394,"start":395,"enrollment":62,"conditions":396,"interventions":397},"NCT03768115","Autologous Plasma Treatment for Severe Dry Eye Patients","WITHDRAWN",[50],"2020-10-14","2018-11-01",[18],[385],{"trials":399,"activeCount":62},[],{"trials":401,"activeCount":62},[],{"trials":403,"activeCount":62},[],{"trials":405,"activeCount":62},[],{"trials":407,"activeCount":62},[],{"intervention":409,"totalTrials":58,"cells":410},"Wei's Qi Ju Gan Lu Formula",{"EARLY_PHASE1":411,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":430},{"trials":412,"activeCount":62},[413],{"nctId":414,"briefTitle":415,"status":161,"phases":416,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":421},"NCT05319041","Herbal Medication to Treat Dry Eye in Peri\u002F Post-menopausal Women",[50],"2025-02-21","2022-04-11",150,[18],[409],{"trials":423,"activeCount":62},[],{"trials":425,"activeCount":62},[],{"trials":427,"activeCount":62},[],{"trials":429,"activeCount":62},[],{"trials":431,"activeCount":62},[],{"intervention":433,"totalTrials":58,"cells":434},"Latanoprost-Bimatoprost",{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":436,"activeCount":62},[],{"trials":438,"activeCount":62},[],{"trials":440,"activeCount":62},[],{"trials":442,"activeCount":62},[],{"trials":444,"activeCount":62},[],{"trials":446,"activeCount":62},[447],{"nctId":448,"briefTitle":449,"status":233,"phases":450,"completion":451,"start":452,"enrollment":453,"conditions":454,"interventions":456},"NCT00567788","Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study",[55],"2008-07","2006-07",60,[455],"Glaucoma, Angle-Closure",[433,457],"Bimatoporost-Latanoprost",{"intervention":457,"totalTrials":58,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":470},{"trials":461,"activeCount":62},[],{"trials":463,"activeCount":62},[],{"trials":465,"activeCount":62},[],{"trials":467,"activeCount":62},[],{"trials":469,"activeCount":62},[],{"trials":471,"activeCount":62},[472],{"nctId":448,"briefTitle":449,"status":233,"phases":473,"completion":451,"start":452,"enrollment":453,"conditions":474,"interventions":475},[55],[455],[433,457],{"intervention":477,"totalTrials":58,"cells":478},"Aflibercept + reduced fluence photodynamic therapy",{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":487,"NA":489},{"trials":480,"activeCount":62},[],{"trials":482,"activeCount":62},[],{"trials":484,"activeCount":62},[],{"trials":486,"activeCount":62},[],{"trials":488,"activeCount":62},[],{"trials":490,"activeCount":62},[491],{"nctId":492,"briefTitle":493,"status":161,"phases":494,"primaryCompletion":495,"completion":495,"start":496,"enrollment":453,"conditions":497,"interventions":498},"NCT03941587","Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment",[55],"2024-06-06","2021-02-01",[24],[477,499],"Aflibercept + sham reduced fluence photodynamic therapy",{"intervention":499,"totalTrials":58,"cells":501},{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":503,"activeCount":62},[],{"trials":505,"activeCount":62},[],{"trials":507,"activeCount":62},[],{"trials":509,"activeCount":62},[],{"trials":511,"activeCount":62},[],{"trials":513,"activeCount":62},[514],{"nctId":492,"briefTitle":493,"status":161,"phases":515,"primaryCompletion":495,"completion":495,"start":496,"enrollment":453,"conditions":516,"interventions":517},[55],[24],[477,499],{"intervention":519,"totalTrials":58,"cells":520},"Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo",{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":522,"activeCount":62},[],{"trials":524,"activeCount":62},[],{"trials":526,"activeCount":62},[],{"trials":528,"activeCount":62},[],{"trials":530,"activeCount":62},[],{"trials":532,"activeCount":62},[533],{"nctId":534,"briefTitle":535,"status":161,"phases":536,"primaryCompletion":451,"completion":451,"start":537,"enrollment":352,"conditions":538,"interventions":540},"NCT00348413","Thyroid Treatment Trial",[55],"2003-06",[539],"Graves Ophthalmopathy",[519],{"intervention":542,"totalTrials":58,"cells":543},"Ganciclovir",{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":552,"NA":554},{"trials":545,"activeCount":62},[],{"trials":547,"activeCount":62},[],{"trials":549,"activeCount":62},[],{"trials":551,"activeCount":62},[],{"trials":553,"activeCount":62},[],{"trials":555,"activeCount":62},[556],{"nctId":557,"briefTitle":558,"status":161,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":568},"NCT01647529","Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis \u002F Endotheliitis",[55],"2013-07","2014-07","2012-07",29,[565,566,567],"Cytomegalovirus Anterior Segment Infection","Anterior Uveitis","Endotheliitis",[542]]